Barrx RF Ablation system success in Barrett's Oesophagus
Covieden has announced that results from a prospective, multicenter, randomized, controlled clinical trial (The SURF Trial -SUrveillance vs. RadioFrequency ablation)which showed that endoscopic ablation therapy using the Barrx RF Ablation System is effective at eliminating Barrett's Oesophagus, a pre-cancerous condition of the oesophagus, and preventing disease progression.
The authors reported that endoscopic ablation therapy resulted in a 94% relative risk reduction in disease progression, compared to controls (1.5% progression in ablation group vs. 25.0% progression in control group) over a two-year follow-up period.Other endpoints included resolution of Barrett's tissue and occurrence of adverse events. At last endoscopy visit, 90% of patients treated with ablation were free of all signs of Barrett's Oesophagus tissue, while none of the patients in the control group demonstrated resolution of Barrett's tissue.
Kai Yi N. Phoa, M.D., presented the outcomes data (Abstract #1004) at Digestive Disease Week 2013, part of an American Gastroenterological Association research forum.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins